RxDoctor Payments Data

Stacey Lopez, PA

Physician Assistant · Burleson, TXNPI 1134769292

Payments from drug & device makers

$18,643in general payments, 2019–2025

Across 741 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sanofi$2K
  • Johnson & Johnson$2K
  • Amgen$1K
  • LEO Pharma Inc.$1K
  • Lilly USA, LLC$1K
  • plus $8K from 24 others

What the payments were for

  • Consulting fees$4062%
  • Speaking & faculty fees$991%
  • Food & beverage$17,71795%
  • Education$4212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,643 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$124,104
Medicare patients
417
Services billed
4,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$274,220
OtezlaApremilast21$102,627
Ketoconazole284$4,511
Clobetasol Propionate139$4,038
Tacrolimus33$2,956
Betamethasone Dipropionate35$1,368
Metronidazole11$1,313
Doxycycline Hyclate77$1,272
Tretinoin17$1,033
Clindamycin Phosphate38$921
Triamcinolone Acetonide135$912
Ciclopirox32$859
Mupirocin77$700
Spironolactone22$336
Ammonium Lactate16$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,322$102,62721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →